Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin and Capecitabine Induction followed by CCRT for Nasopharyngeal Carcinoma
NCT03427359Phase 2Completed
- Sponsor
- The University of Hong Kong-Shenzhen Hospital
- Start
- Jan 2015
- Primary completion
- Dec 2017
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
01
Overview
A Phase 2 trial of cisplatin, capecitabine in nasopharyngeal carcinoma (NPC), sponsored by The University of Hong Kong-Shenzhen Hospital. Started Jan 2015; status: completed.
02
Drugs
cisplatincapecitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03427359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03427359.